SciClone Pharmaceuticals
Manufacturing · China · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
22f Central Plaza 381 Middle Huaihai Rd,...Phone Number
+852 25100118Website
www.sciclone.comRevenue
$433.5 MillionStock Symbol
6600.HKIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About SciClone Pharmaceuticals
Founded in 1989, SciClone Pharmaceuticals is headquartered in Foster City, California. SciClone Pharmaceuticals focuses on the development and marketing of immunology and oncology therapies.Explore more
SciClone Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SciClone Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if SciClone Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if SciClone Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when SciClone Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at SciClone Pharmaceuticals
Earning: See what the market has to say on SciClone Pharmaceuticals recently announced quarterly report
Funding: Get notified immidiatlly once SciClone Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Click to see if SciClone Pharmaceuticals had a recent Job posting/layoffs
SciClone Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
SciClone Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SciClone Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SciClone Pharmaceuticals.
SciClone Pharmaceuticals Tech Stack
A closer look at the technologies used by SciClone Pharmaceuticals
See more technologies
Most Recent Scoops
Partnership
Partnership, Product Management, Intellectual Property, Legal Affairs, Omnichannel, Pharmaceuticals, Channel Sales
Partnership
Partnership
Left Company
Executive Move
Wilson W. Cheung, Chief Financial Officer & Senior VP, Finance, has left the organization.
Executive Moves, Personnel Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire, Personnel Moves
SciClone Pharmaceuticals News & Media
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
Vibativ® is a life-saving antibiotic for pneumonia and serious skin infections Approval in China paves the way for launch in world's second-largest market NASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc....USD1.13bn privatisation from HKSE of SciClone - Slaughter and May
Slaughter and May is advising on the USD1.13billion privatisation from HKSE of SciClone PharmaceuticalsMenarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
FLORENCE, Italy & HONG KONG--(BUSINESS WIRE)--The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and SciClone Pharmaceuticals (Holdings) Ltd. (“SciClone”), an international biopharmaceutical company, today announced that they have entered into an exclusive sub-licensing agreement to develop and commercialize ORSERDU® (elacestrant) in the People’s Republic of China (China), in an effort to expand treatment options for appropriate metastatic breast caMenarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections
Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in China The deal brings together Melinta's innovation, Menarini's cross-regional expertise in registration and...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SciClone Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Founded in 1989, SciClone Pharmaceuticals is headquartered in Foster City, California. SciClone Pharmaceuticals focuses on the development and marketing of immunology and oncology therapies.... Read More
